MPAM
ATRS

Monarch Partners Asset Management’s Antares Pharma, Inc. ATRS Stock Holding History

Monarch Partners Asset Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-167,820
Closed -$561K – 207
2019
Q3 		$561K Buy
167,820
+56,770
+51% +$187K 0.08% 146
2019
Q2 		$365K Hold
111,050
– – 0.05% 157
2019
Q1 		$336K Buy
+111,050
New +$360K 0.05% 166

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Monarch Partners Asset Management's ATRS Position: Q4 2019 in Review

Monarch Partners Asset Management sold out of Antares Pharma, Inc. (ATRS) in Q4 2019, closing a stake of 167,820 shares — an estimated $561K sold.

Monarch Partners Asset Management first reported a position in ATRS in Q1 2019 and held it in 3 quarters. The position peaked at $561K in Q3 2019. 160 funds tracked by Wall St. Rank hold ATRS as of Q4 2019.

  • Monarch Partners Asset Management reported no remaining Antares Pharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Monarch Partners Asset Management sold 167,820 Antares Pharma, Inc. shares in Q4 2019, an estimated $561K.
  • Monarch Partners Asset Management first reported a position in Antares Pharma, Inc. in Q1 2019 and held it in 3 quarters.
  • Monarch Partners Asset Management's Antares Pharma, Inc. position peaked at $561K in Q3 2019.
  • 160 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2019.

Based on Monarch Partners Asset Management's 13F filing for Q4 2019, filed 5 Feb 2020.